NCT04637477已完成不适用
Rush Coronavirus Disease Virtual Lifestyle Program to Boost Host Resistance in Patients With Elevated Cardiometabolic Risk: A Proof-of-Concept Study
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Fifty percent of participants will lose >5% of baseline weight after completing the intervention at 3 months.
研究概览
简要总结
This is a proof-of-concept study of a virtual version of a lifestyle intervention aimed at reducing cardiometabolic risk in patients with the Metabolic Syndrome (MetS). The aim is to recruit 12 patients at high risk for coronavirus infection based upon a diagnosis of obesity and the MetS, conduct a 12-week virtual version of the in-person intervention, and explore efficacy using clinically significant pre-specified targets for weight, diet, physical activity, stress, and markers of inflammation. In addition, the investigators will explore safety, fidelity, feasibility, and acceptability.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Men and women with components of the metabolic syndrome, defined by an adapted version of the Joint Interim Statement of the IDF, NHLBI, AHA, WHF, IAS, IASO (Alberti, 2009). Surrogates for waist circumference and fasting glucose were selected to help identify prospective participants using medical records. Participants must have ≥ 2 of the following five criteria to participate in the study:
- •Waist circumference based on AHA/NHLBI (ATP III) cut points of ≥ 102 cm for men and ≥ 88 cm for women or BMI≥30
- •Triglycerides ≥150 mg/dL or treatment for elevated triglycerides
- •HDL cholesterol <40 mg/dL in men or <50 mg/dL in women, or treatment for low HDL
- •Systolic blood pressure ≥130 m Hg, diastolic blood pressure ≥85 mm Hg, or treatment for hypertension
- •Fasting plasma glucose 100-125 mg/dL (range inclusive), or on metformin, or HbA1c between 5.7 and 6.
- •Age 18 years or older
- •Highly motivated to make lifestyle changes as a way to manage the MetS.
排除标准
- •Individuals who report being unable to walk 2 consecutive blocks without assistance are ineligible. Additionally, individuals who endorse pain, tightness, or pressure in their chest during physical activity (on question 1 of the EASY screener) or current dizziness or lightheadedness (on question 2 of the EASY screener) may not be randomized without providing documentation in writing from their physician indicating that they have been cleared for participation in the trial.
- •Unwilling, unable, or not ready to make the lifestyle changes prescribed in ELM
- •BMI <27 or > 40
- •Weight > 397 lbs. The Fitbit Aria scale, utilized in the intervention, measures up to 397 lbs.
- •Unable to consistently attend group classes at the anticipated time due to schedule conflicts or other reasons.
- •Unable or unwilling to give an informed consent or communicate with study staff.
- •Unable or unwilling to complete accelerometer data collection.
- •Does not have reliable access to the internet.
- •Does not have a smart phone. Must be willing to download the Fitbit app on their smart phone.
- •Not fluent in English
- •Current diagnosis of type 1 or type 2 diabetes, on any diabetes medications except metformin, or has a screening A1c ≥6.5
- •Inpatient treatment for a psychiatric condition within the past 6 months, or currently receiving treatment for schizophrenia or other serious psychiatric illness
- •Probable major depression, defined as a PHQ-8 score ≥10
- •Pregnant women, planning a pregnancy in the next 2 months, given birth in the last 6 months, or currently breastfeeding
- •≥ 30 total days of oral corticosteroid use within the last year, history of solid organ transplant, or history of stem cell transplant
- •Problematic use of alcohol and/or recreational drugs, defined as ASSIST screening score of ≥
- •Self-reported or known history of an eating disorder (e.g., binging and purging) in the past 5 years
- •Use of weight loss medications (Qsymia, orlistat, phentermine, Saxenda, etc.) in the last 3 months, or unwilling to abstain from taking weight loss medications or supplements during the trial
- •History of bowel resection surgery or bariatric surgery
- •Any medical condition known to influence the etiology of MetS as judged by the study physician (e.g., uncontrolled hypothyroidism, endocrine hypertension, etc)
- •History of major cardiovascular illness, including: a) stroke; b) myocardial infarction; c) congestive heart failure requiring hospitalization, or greater than NYHA heart failure class I; d) uncontrolled hypertension (SBP>180 or DBP > 109); e) unstable angina or an active prescription for sublingual nitroglycerin; or f) other major cardiovascular illness which the site PI determines could limit ability to participate in the trial. Individuals screened for participation, whose screening systolic blood pressure is ≥160 and ≤179, or whose screening diastolic blood pressure is ≥100 and ≤109 are considered to have MODERATE, or Stage 3 Hypertension. If they otherwise qualify and wish to participate in ELM, they will be referred to their physician for clearance prior to randomization.
- •Cognitive impairment
- •Visual or hearing impairment
- •Currently taking or expecting to take any of the following exclusionary medications:
- •Antiretroviral therapy (e.g., HAART)
- •Weight loss medications (as in #14)
- •Medications known to significantly influence weight or metabolic outcomes
- •Diabetes drugs other than metformin (as in #7)
- •Receiving dialysis
- •Cancer treatment within the last 6 months, excluding chemoprophylaxis or treatment for non-melanoma skin cancer
研究组 & 干预措施
Virtual ELM
Experimental
干预措施: Virtual ELM (Behavioral)
结局指标
主要结局
Fifty percent of participants will lose >5% of baseline weight after completing the intervention at 3 months.
时间窗: 3 months after baseline assessment
Weight is recorded in kilograms to the nearest 0.1 kg using a flat scale.
次要结局
- Remission of components of metabolic syndrome(Measured at 3 months from baseline)
- Vegetable consumption(Measured at 3 months from baseline)
- Physical activity(Measured at 3 months from baseline)
- Facets of Mindfulness(Measuring change from baseline mindfulness at 3 months)
- Habit formation(Measured at 3 months after baseline)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Virtual Lifestyle Program Evaluation During Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Cardiometabolic SyndromeWeight LossNCT04784624University of Manitoba100
尚未招募
不适用
A Virtual Post-Discharge Intervention For Patients With CKDChronic Kidney DiseasesNCT05274347McMaster University30
进行中（未招募）
不适用
The Lifestyle Exercise and Diet Trial (LEAD) 2.0Subjective Cognitive DeclineNCT06078748University of Waterloo140
尚未招募
不适用
Behavioral Intervention for Lifestyle Physical Activity in Parkinson's DiseaseParkinson Disease (PD)NCT06603012University of Illinois at Chicago50
招募中
不适用
Lifestyle Intervention in Patients With Metastatic Prostate CancerProstate CancerNCT05850182Oncology Institute of Southern Switzerland30